Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective analysis.

Real-world treatment with liso-cel showed a broad spectrum of outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who ...

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

With a link to specific genetic mutations in myelodysplastic syndromes, tobacco smoking may be associated with disease progression and survival.

By addressing these issues, we can ensure that all patients, regardless of their socioeconomic status, have the opportunity ...

Meta: Blinatumomab plus chemotherapy, vs chemotherapy alone, significantly improved DFS rates and was well tolerated in ...

Treatment with bicistronic CD19/CD22-directed CAR T-cell therapy appeared safe and effective with high remission rates among children with relapsed/refractory B-ALL. A novel bicistronic ...

The FDA set a PDUFA date for glofitamab in relapsed or refractory diffuse large B-cell lymphoma for July 20, 2025. The FDA has accepted the supplemental biologics license application (sBLA) for ...